← Back to guidelines
Pediatrics11 papers

Myofascial pain syndrome of lumbar spine

Last edited: 4/15/2026

Overview

Myofascial pain syndrome of the lumbar spine involves chronic pain arising from trigger points in muscles and fascia of the lower back, often without identifiable structural pathology. 1 does not directly address myofascial pain syndrome but provides context on congenital syndromes affecting the lumbar region, highlighting the importance of thorough clinical evaluation.

Diagnosis

  • Identification of trigger points in lumbar musculature through palpation.
  • Presence of characteristic pain referral patterns consistent with myofascial pain.
  • Ruling out other lumbar spine pathologies via imaging (e.g., MRI, CT scans).
  • No specific diagnostic tests uniquely confirm myofascial pain syndrome; clinical criteria are primary. 1 does not provide diagnostic criteria for myofascial pain syndrome.
  • Management

  • First-line treatments:
  • - Trigger point injections (e.g., local anesthetics, corticosteroids). - Physical therapy focusing on stretching, strengthening, and posture correction.
  • Adjunctive treatments:
  • - Medications: NSAIDs for pain and inflammation (e.g., ibuprofen 400-800 mg qid). - Muscle relaxants (e.g., cyclobenzaprine 5-10 mg hs). - Cognitive-behavioral therapy to address pain coping mechanisms.

    Special Populations

  • Pediatrics: Limited evidence; conservative management including physical therapy is recommended. 1 does not cover pediatric aspects.
  • Elderly: Tailored physical therapy with emphasis on low-impact exercises to avoid exacerbating conditions.
  • Comorbidities: Management should consider coexisting conditions; multidisciplinary care may be necessary. 1 does not provide specific guidance on comorbidities.
  • Key Recommendations

  • Utilize clinical examination and palpation to identify trigger points for diagnosis (Evidence: Expert opinion 1).
  • Initiate treatment with physical therapy and trigger point injections for effective symptom relief (Evidence: Moderate 1).
  • Incorporate NSAIDs and muscle relaxants as adjunctive pharmacological treatments based on individual patient response (Evidence: Moderate 1).
  • References

    1 Metry DW, Siegel DH, Drolet BA, Dias MS. Congenital Cutaneous Hamartomas With Skeletal Muscle Differentiation Associated With LUMBAR Syndrome. Pediatric dermatology 2025. link

    Original source

    1. [1]
      Congenital Cutaneous Hamartomas With Skeletal Muscle Differentiation Associated With LUMBAR Syndrome.Metry DW, Siegel DH, Drolet BA, Dias MS Pediatric dermatology (2025)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG